Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 5/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446495 | 1.00 | GRM2 (0.49) | GRM2KIF11TDP2 | |
| SCHEMBL29709236 | 0.74 | CYP3A4 (0.50) | GRM2 | |
| SCHEMBL4750486 | 0.72 | GRM2 (0.42) | GRM2KIF11TDP2 | |
| SCHEMBL5606248 | 0.72 | GRM2 (0.38) | GRM2KIF11 | |
| SCHEMBL17026980 | 0.72 | PNMT (0.38) | KIF11TDP2 | |
| SCHEMBL2324023 | 0.72 | ALDH1A1 (0.47) | — | |
| SCHEMBL6756077 | 0.71 | KIF11 (0.49) | GRM2KIF11TDP2 | |
| SCHEMBL31734651 | 0.70 | TDP2 (0.54) | GRM2KIF11TDP2 | |
| SCHEMBL9556590 | 0.70 | JUN (0.43) | GRM2TDP2 | |
| SCHEMBL3224720 | 0.69 | TDP2 (0.66) | GRM2KIF11TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235547-B2 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | GRM2, GRIK2, GRIA2 | GRM2 1/4885KIF11 2928/4885TDP2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.